Mercury Laboratories Ltd Share Price: June 2026 Quarter Deep Dive

Nidhi Thakur

July 25, 2026

Key Takeaways

Mercury Laboratories posted June 2026 standalone net profit of Rs 0.30 crore, down 69.07% year-on-year.
Sales declined to Rs 15.96 crore as operating margins compressed from 13.01% to 7.46%.
Key profitability metrics fell: PBDT down 53%, PBT down 75%, NP down 69% year-on-year.
Retail investors should monitor mercury laboratories ltd share price alongside quarterly signals for updated cues.

For traders watching the mercury laboratories ltd share price, the June 2026 quarter reveals a sharp drop in profitability, even as sales shrink. The standalone net profit declined 69.07% to Rs 0.30 crore in the quarter ended June 2026, compared with Rs 0.97 crore in the quarter ended June 2025. Sales contracted 12.02% year-on-year to Rs 15.96 crore, underscoring a challenging quarter for the company. This combination of lower profit and slower revenue raises questions on margin management, product mix, and cost control.

Mercury Laboratories Ltd Share Price Movement In June 2026 Quarter

The June 2026 quarter paints a cautious picture for the mercury laboratories ltd share price, with profitability compressing amid a softer topline. Specifically, the company reported

Sales: Rs 15.96 crore in Jun 2026 and Rs 18.14 crore in Jun 2025. Net Profit: Rs 0.30 crore in Jun 2026 vs Rs 0.97 crore in Jun 2025. OPM: 7.46% in Jun 2026 vs 13.01% in Jun 2025. PBDT: Rs 1.12 crore in Jun 2026 vs Rs 2.39 crore in Jun 2025. PBT: Rs 0.39 crore in Jun 2026 vs Rs 1.55 crore in Jun 2025. Net Profit: Rs 0.30 crore in Jun 2026 vs Rs 0.97 crore in Jun 2025.

Download App Now

Mercury Laboratories Standalone Results June 2026 Key Metrics And Trends

The standalone performance in the June 2026 quarter shows margin compression and a clear drop in profitability, even as revenue contracted. The numbers tell a story of a business under pressure from both top-line softness and tighter margins.

Metric	June 2026	June 2025	YoY Change
Sales (Rs Cr)	15.96	18.14	-12.0%
OPM %	7.46%	13.01%	-5.55 pp
PBDT (Rs Cr)	1.12	2.39	-53.0%
PBT (Rs Cr)	0.39	1.55	-75.0%
NP (Rs Cr)	0.30	0.97	-69.0%

Download App Now

Year-Over-Year Comparison For Mercury Laboratories June 2026 Quarter

Compared with the June 2025 quarter, all major profitability metrics deteriorated. Sales slipped by 12% to Rs 15.96 crore, PBDT fell by 53%, PBT by 75%, and net profit by 69%. The drop in operating margin (OPM) from 13.01% to 7.46% highlights the margin compression that accompanied the revenue decline. Retail investors should weigh these shifts when assessing the stock's medium-term risk-reward.

Investing Implications For Mercury Laboratories Ltd Share Price And What To Watch

For retail investors, the June 2026 quarterly results signal caution for the mercury laboratories ltd share price. A steep profit decline and margin erosion can weigh on the stock's valuation, especially if the revenue headwinds persist. Traders should watch whether management can stabilise margins while the top line remains under pressure. In such scenarios, a diversified approach that emphasizes quality earnings and sustainable margins often pays off more reliably than chasing quarterly price spikes. The presence of a SEBI-registered broker like Swastika Investmart can help investors access balanced research and practical tools for portfolio decisions. You can also explore Swastika's Sarthi AI stock assistant.

Frequently Asked Questions

What were Mercury Laboratories' June 2026 quarter standalone results in terms of net profit and sales?

Standalone net profit was Rs 0.30 crore in June 2026, down 69.07% from Rs 0.97 crore in June 2025, while sales were Rs 15.96 crore in June 2026, down 12.02% from Rs 18.14 crore in June 2025.

How did the June 2026 quarter's operating profit margin compare with the prior year?

OPM declined from 13.01% in June 2025 to 7.46% in June 2026.

What were the year-on-year changes in PBDT, PBT and net profit for Mercury Laboratories in June 2026?

PBDT fell 53%, PBT fell 75%, and net profit fell 69% year on year.

How should retail investors interpret Mercury Laboratories' June 2026 results in relation to the Mercury Laboratories share price?

The results indicate margin compression and profit decline, which can weigh on the Mercury Laboratories share price unless supported by margin stabilization and revenue resilience.

Where can investors access AI-driven stock research from Swastika for Mercury Laboratories and other stocks?

Investors can use Swastika's Sarthi AI stock assistant for AI-driven research and scenario planning:Swastika's Sarthi AI stock assistant.

Conclusion

The June 2026 quarter for Mercury Laboratories underscores a tougher operating environment where profit declines and margin compression overshadow topline declines. For a retail investor, the key takeaway is to treat this quarter as a data point that informs a broader risk-management approach rather than a standalone catalyst for a buy-or-sell decision. A prudent next step is to adjust expectations for near-term profitability while maintaining discipline around valuation, quality of earnings, and cash flow visibility.

Open your trading and demat account here

Reference :

1 : Business Standard

DISCLAIMER:

^{The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investmart Ltd. (“SIL”). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus (“RHP”) issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor’s particular circumstances before making any decisions on the investment. The Investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document must bear in mind that past performances if any, are not indicative of future results. The actual returns on investment may be materially different than the past. Investments in Securities market products and instruments including in the IPO of the Company are highly risky and they are generally not an appropriate avenue for someone with limited resources/ limited investment and low risk tolerance. Such Investments are subject to market risks including, without limitation, price, volatility and liquidity and capital risks. Therefore, the users of this document must carefully consider all the information given in the RHP including the risks factors before making any investment in the Equity Shares of the Company.Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.CORPORATE & ADMINISTRATIVE OFFICE - 48, Jaora Compound, M.Y.H. Road, Indore - 452 001 | Phone 0731 - 6644000 Compliance Officer: Dimple Soni. Email: compliance@swastika.co.in Phone: (0731) 6644 241 Swastika Investmart Limited, SEBI Reg. No. : NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532 CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713. Research Analyst Registration Number: INH000024073}